Evaxion A/S (EVAX) Earnings Call Transcript
May 7, 2026
Earnings Call Speaker Segments
Thanks, and hello everybody, welcome to the Q1 2026 Business Update Call for Evaxion. It's a real pleasure to have with me our CSO Birgitte Rønø, our COO — who was promoted not long ago, and we'll get into that — plus Thomas Schmidt, our CFO, and Mads Kronborg, who leads Investor Relations and Communications. Let's go to slide one, just so you know the lay of the land for what's coming. We'll take a bit of time on what we achieved during this year's first quarter, along with several important shifts we've implemented so we can tackle our strategy and keep it in focus. After that I'll pass things to Birgitte, and she'll discuss a few recent standout items from our R&D portfolio related to the AI-Immunology platform. From Birgitte, Thomas takes over and guides you through the financial results for Q1; following that come a few closing thoughts, and then we'll take your questions. On the next slide, just to repeat it, forward-looking statements might be made during today's call, and everyone listening, investors included, should look to the documents we've filed with the SEC. Skipping past the intro to slide 5. As I've done previously, I wanted to stress the four areas the organization treats as key priorities and give a feel for the momentum as we give an update on each one. To begin with, our central priority of business development and partnering is well underway and has been reinforced by how we've rearranged the organization somewhat — I'll get to that — so we concentrate on reaching outward and positioning the company before a wider audience, while also boosting awareness of precisely what Evaxion is capable of delivering when it comes to products and the platform. Happily, lots of conversations are in progress on that front, and we're hoping to share more as this year moves along. Second, on the R&D side, we're thrilled to discuss fresh data from the phase II study of EVX-01, our lead program, where we recently managed to update certain translational data at AACR. Birgitte will go deeper into how the cells we manufacture perform relative to the vaccines administered to patients, and the 86% immunogenicity conversion rate there. At AACR we could also present a new preclinical data set, done together with our collaborators at Duke University, on the potential for applying the AI platform to Glioblastoma; we've long believed this approach might work for other tumors with high mutational burden, and also for ones where high mutational burden isn't present. That's largely how we managed to show the platform's wider applicability in Glioblastoma. Once again, Birgitte will say more about that. To wrap up, we can now verify that the final patient has completed their last visit in the extension portion of both our EVX-01 initiative and our phase II study. There will be additional updates on this before the year is out. On a wider note regarding the AI-Immunology platform, we kept refining and reinforcing its capacity to produce offerings spanning our infectious disease and oncology pipelines, plus autoimmune disease as well, where updates are also expected later in the year. During Q1, I'm pleased to report that we shared some preliminary findings on a novel polio vaccine candidate, which was presented alongside the Gates Foundation. And last, as Thomas will discuss, we've kept up our rigorous approach to resource allocation, in line with the objectives we've set out for the portfolio and platform, and our cash runway stays the same, extending into the second half of 2027. Turning to slide 6. As I noted, we've made some slight adjustments within the company. I'm happy to share that Birgitte Rønø has been promoted into the merged position of CSO and COO, which genuinely mirrors the way we structure the business and how effectively it has operated lately, while also allowing me, in particular, to devote more attention outwardly on the company's behalf when it comes to business development and engaging with investors. At the same time, and independently, we had the pleasure of adding Jens Bitsch-Nørhave to our board of directors. Jens Bitsch-Nørhave brings an enormous depth of expertise in BD, corporate strategy, and outreach overall, from a biotech standpoint as well as, more recently, from J&J and Homrie, where he currently serves as Corporate VP and Global Head of Corporate Development. We're very pleased with how we've managed to reinforce the organization, keeping our focus on the strategy we've laid out — to build and sustain what we have while forging stronger partnerships. On slide 7, to recap, we continue to be a streamlined, skilled, and dedicated group when it comes to the management team. Two of those members are joining me on this call right now. Andreas keeps supporting and propelling the company's innovation strategy related to AI-Immunology. Our board is unchanged, except for the addition of Jens, as I referenced. Now to slide 8, to lay out our goals and key milestones for the year. As a quick reminder, Evaxion has, across many years, earned the distinction of holding a phase II pipeline in oncology, featuring our EVX-01 asset for advanced melanoma — our personalized neoantigen-directed peptide-based vaccine — where the data is excellent, and Birgitte will speak to both the current status and what lies ahead; we also have our EVX-03 program, combining personalized and ERV-based antigens on our DNA platform. Beyond that, we have our off-the-shelf vaccine program, EVX-04, advancing through preclinical development with the goal of clinical readiness by the close of this year, aimed at AML, and designed as a single vaccine approach for multiple AML patients. More details to follow on that. On the infectious disease side, our attention stays on advancing the preclinical assets we have. There's EVX-B1, which targets the pathogen Staphylococcus aureus, and EVX-B2, aimed at Neisseria gonorrhoeae. We're also working with Aphrogen on an RNA platform. EVX-B3 is our optioned partnered program, and it keeps progressing together with MSD. As for EVX-B4, the newer program we started more recently against Group A Streptococcus, it's achieving excellent momentum in the initial design work for the early discovery component. Our first viral program keeps moving ahead when it comes to verifying the candidate components. There is a great deal happening across the organization. On slide 9, I simply wanted to remind everyone listening about the milestones we've set for 2026, and about the fact that the first of them has already been reached through our EVX-01 additional biomarker and immunogenicity data. We are still on schedule regarding an update on the AI-Immunology approach in autoimmune disease, the 3-year data from our EVX-01 melanoma program, the strategy we have planned for the EVX-04 AML program, and the early work that is maturing in our preclinical EVX-B4 program against Group A Streptococcus. At the core, we are pursuing the partnership strategy with a focus on the platform and the assets, so that we can keep building value within the company and concentrate on bringing those into early development, where we think we can contribute value. With that, I'd like to pass things to Birgitte, who will walk you through our R&D and AI-Immunology update.
Thanks, Helen. My focus today is going to be on EVX-01, our lead candidate. As was said, this is the personalized neoantigen cancer vaccine we currently have in phase II for advanced melanoma. After that, I'll walk you through some exciting new data that shows how our AI-Immunology platform can scale into glioblastoma, a deadly brain cancer that's hard to treat. And finally, I'll show you how we've used AI-Immunology to design optimized vaccine antigens for a better polio vaccine. Next slide, please. As Helen said, back in April at the AACR annual meeting here, we presented new phase II biomarker and T cell data for EVX-01. During our update, we shared that a specific immune reaction was generated by 86% of the vaccine targets in EVX-01 — a figure well above what other comparable vaccine candidates have demonstrated. Beyond that, we noted that de novo T cell responses were brought about by 86% of the immunogenic vaccine targets, meaning EVX-01 is directly responsible for sparking entirely new T cell responses instead of merely boosting ones that were already present. This is highly significant, since clinical benefit has been linked to the generation of such novel responses. Additionally, a positive correlation was demonstrated by us between how strong the T cell response was that those targets produced and the anticipated quality of EVX-01's vaccine targets. That very high rate of success for vaccine targets, combined with the positive correlation, demonstrates just how powerful our AI-Immunology platform is when it comes to prediction. Let's move to the next slide. EVX-01 continues to produce robust results, strengthening a body of clinical and immunological evidence that is both already in place and encouraging. Last year at ESMO, we shared an overall response rate of 75%, encompassing 25 complete responders along with 92 sustained responses, which indicates lasting benefit. Notably, after receiving EVX-01, over 50% of patients shifted toward a better clinical response; and with the phase II immune data we've just presented, that picture gains even more support from the 86% immunogenicity and the 86 de novo immune responses, revealing immune activation that is both broad and consistent. As we look to the future, the path we're taking for development is well defined. In the latter half of 2025, we intend to share 3-year data that will include clinical outcome. Past that point, we are assessing and holding discussions about other cancer indications of relevance, and we anticipate that additional trials will be run through partnerships. A key point is that EVX-01 holds FDA Fast Track designation already, and that speaks to both the unmet need and the potential for development. Taking everything together, as we progress into the coming stages of value creation, this gives EVX-01 a very strong position. Could we go to the next slide? Now let's shift our attention to the other encouraging data set that was presented at AACR. Through work done jointly with Duke University, we showed that our AI-Immunology platform can extend past melanoma, and in this instance that is illustrated by a glioblastoma, or GBM. Glioblastoma, or GBM, ranks as the most frequent and most aggressive malignant tumor that starts in the brain. Even when patients undergo surgery and then chemoradiation, their outcomes stay very poor; median overall survival comes in at roughly 15 months, and fewer than 10% of patients are alive at 5 years. Using our AI-Immunology platform, we looked at tumor omics data from 24 GBM patients and demonstrated that a completely personalized vaccine design was feasible in all 24 of those cases. The crucial point is that these designs relied on 2 categories of antigens: classical neoantigens, together with antigens derived from the dark genome, which are called Endogenous retroviruses, or ERVs. Both types of antigens showed up in 21 of the 24 designs. 2 vaccine designs contained neoantigens alone, while 1 design was built entirely around ERV antigens. This analysis demonstrates how flexible and scalable the platform is when it comes to integrating antigens from various sources and matching each patient's tumor biology. Taken together, the data show AI-Immunology can tackle hard-to-treat, low mutational burden tumors such as GBM, and it also points to broader applicability of the platform across different cancers. Please move to the next slide. A further illustration of how AI-Immunology can be used to design improved vaccines was presented at the World Vaccine Congress. Alongside the Gates Foundation, we shared a new polio vaccine, a new polio vaccine concept built with AI-Immunology. We developed a brand-new hybrid capsid antigen along with a brand-new de novo T cell antigen, with the goal of producing a potent, wide-ranging humoral response covering every serotype. When you put it all together, this points to what AI-Immunology could achieve in reimagining traditional vaccines — making them simpler while also widening their reach. Let's move to the following slide. Having covered the advances made throughout our main R&D program, we should pause here and turn our attention to AI-Immunology itself, and to the evidence confirming it can produce product candidates of high quality. AI-Immunology has been validated in the clinic, delivering favorable results across three of three oncology studies. In preclinical studies, we've shown proof of concept in a number of disease areas. That includes cancer, through our off-the-shelf vaccine approach that targets ERV, and it also includes infectious diseases, where we have several vaccine candidates aimed at various bacterial and viral pathogens. A key point: EVX-01 is highly scalable and could work in other solid tumors, meaning beyond melanoma. On top of that, the platform's usefulness in difficult cancer indications got additional validation in GBM. And lastly, AI-Immunology can handle multiple modalities — peptides, proteins, and DNA as well as RNA — which opens up possibilities for our pipeline and for partnerships too. To wrap up, we've shown solid momentum throughout both our platform and our research and development pipeline. We're eager to keep everyone informed as our programs move ahead. At this point, I'll pass things over to Thomas, who will walk us through the financial results for the quarter.
Yes, thank you, Birgitte. So, as I mentioned, I'll walk you through what we saw in our Q1 26 results. What stands out for the first quarter is the ongoing discipline we've shown in how we allocate our resources. That's naturally in line with our strategy, and it certainly means putting money into our value drivers. It's really tracking according to plan, which also means we're on course to deliver the operational cash burn of about $14 million we expect for 2026. That also highlights and reconfirms that our cash runway extends into the second half of 2027 and stays that way. And as we said before, this doesn't assume any partnerships or deals that we hope to make and tell you about during that period. Turning to the P&L, our operating expenses are overall roughly in line with last year, though a bit lower. That comes from R&D being up slightly, since we keep moving our pipeline and programs forward according to plan, as I mentioned earlier; on the other hand, G&A is a bit lower than last year, mostly because our capital market costs were lower in Q1 2026 than in the same period of 2025. The first quarter gave us a net loss of $3.6 million USD, again, in line with our plan. On the balance sheet, which is the next slide, once again confirming that our cash position and equivalents at quarter end come to $18.4 million, which supports runway into the second half of 2027. Total equity is down since year-end, really because of the net result from the first quarter, so we have $13.2 million in equity at the close of the quarter. Overall, financials are according to plan, allocation goes to our main priorities, and cash runway is confirmed into the second half of 2027; with that, I'll hand it back to Helen for some concluding remarks.
Appreciate it, Thomas, and thank you as well, Birgitte. I want to stress one point: in our view, 2026 has gotten off to an excellent beginning, since we hit the earliest of our milestones, thanks to highly promising translational results from EVX-01. A number of presentations have now been delivered, and these confirm both what the platform can do and how readily it can scale, which Birgitte has walked through. On the business development side, this continues to be a top priority — specifically, talking with organizations about how valuable our assets are and about our ability to advance those assets, something we have touched on somewhat. Our cash runway stays intact into the second half of 2027. We are strictly pursuing the implementation of our strategy along with outside engagement, and the progress is substantial. Having said that, I will turn things back so we can take a few questions through the operator.
Hello, all. I appreciate you answering our questions. I have 2. Regarding the EVX-01 data covering 3 years, clearly ASCO comes too early, yet ought we to expect a readout along the lines of ESMO, or might you present it separately from any larger scientific gathering?
Our update will happen as part of a scientific conference. Doing so apart from one isn't something we plan; once abstracts become available, we'll say which among the 4 conferences that will be.
Understood. That GBM dataset you released, though it's still early, struck me as quite compelling. Clearly, this is an illness area with a major unmet need. Do you plan to advance it into human trials yourselves, or would you look for a collaborator, drawing on what you have so far plus possibly further preclinical work?
That data has us genuinely enthusiastic. We share the view that it's truly intriguing and quite compelling in a disease that's very hard to treat. Our expectation is that this will be a program we pursue with a partner; it reinforces the broader tailored strategy we've built around EVX-01. There will likely be more updates as additional data emerges and talks progress. That one would also follow a partnering path.
Got it. Appreciate it. Thank you.
Thanks. Question.
Hi there, and good morning to all of you. I appreciate your time in answering my questions today. Congratulations on all the wonderful strides you've made.
Thanks so much.
To begin, I want to ask a bit about Evaxion — specifically your approach to design and the strategy behind it. So, when you consider targets for broader cancer indications, is the intention to pursue other conditions where PD-1 has traditionally failed, because of that synergistic effect from steering the antitumor immune response?
Many factors have been factored in by us, I believe. Birgitte, would you like to speak to the way we've been organizing this effort within the company so that we concentrate on the correct diseases?
Like I said, right now we're examining a number of distinct antigen sources. There's more progress happening on this front within the company; our goal is to eventually offer a cancer vaccine to every patient, regardless of what their antigen profile or landscape looks like. To date, we've reviewed over 30 separate indications, charting their mutational burden, their ERV burden, and so on, and what we can see is that for a lot of these indications, using the capabilities we currently have, we're able to design a vaccine of high quality. Naturally, you'd have to dig deeper into medical need and the existing treatment landscapes in order to identify the ideal subpopulations where our therapies would be a good fit. It doesn't have to be a PD-1 low patient — it could be in high as well. Our main focus is on grasping the antigenic landscape and aligning our therapies with those profiles.
Uh-huh. So, whenever you’re considering the creation of fresh vaccines, does it strike you as more logical to employ a single personalized vaccine and afterward check whether you might broaden it to several tumor kinds using that identical vaccine, aiming at wider universal coverage? Or would it be more logical to proceed one tumor at a time and generate a fresh set of targets aimed specifically at the shared target for that particular tumor type, such as melanoma or such as Glioblastoma, and possess a separate vaccine candidate for every one of those distinct cancers?
Oh, not this again. Yeah.
Our strategy here involves examining extensive data from a particular indication and, as I mentioned, getting a clear picture of the landscape. Should we find conserved antigens that are common among patients, then an off-the-shelf vaccine would certainly be something we'd pursue, simply because the logistics are easier and manufacturing costs would be significantly less than what a personalized approach requires. Beyond that, with an off-the-shelf therapy, patients can be treated right away rather than waiting for that personalized batch to become available. All of this ties back to the patient omics data and the profiles we're observing in our analysis. For certain indications, we recognize that creating an off-the-shelf cancer vaccine would be extremely difficult. It really hinges on those various biological profiles.
In my view, Birgitte, the EVX-04 really shows what that situation looks like, since such a substantial degree of conservation has let us make one vaccine for those individuals. Yeah.
Thanks. I appreciate the extra detail. I'm eager for the 3-year data that's due later this year.
Yes. Thank you.
Hello, and congrats on the latest news. Thanks for fielding our questions. You said there are multiple partnerships being pursued in parallel along with ongoing talks. Could you share more about whether those talks are trending toward wide platform licensing or toward collaboration tied to a specific asset? Thanks.
At this stage, clearly, there's a limit to what we can share. As I believe we've said, our priority centers on a partnership for EVX-01, though as you've gathered, in our view its applicability stretches beyond melanoma. Externally, that has clearly drawn interest as well, including through partnering discussions. Within our infectious diseases portfolio, there are, you know, quite a few assets that have caught the attention of multiple companies. Beyond that, we really can't give further specifics. It's fair to say we're aiming to be strategic in how these partnering conversations are handled, with an eye toward maximizing value — whether that comes from an asset group in infectious diseases or from the approach taken with something like a personalized EVX-01, EVX-03 cancer vaccines. Naturally, the moment we're able to share more, we'll be glad to do so. That said, we're pressing ahead firmly on what you could call a more strategic footing regarding how to extract the greatest value from the assets we're able to generate out of AI-Immunology.
Thanks. Only one additional item regarding the Autoimmune platform section. Should we anticipate further specifics during the second half?
Correct; that is what our present plan corresponds to, since as is customary in Evaxion's case, it typically matches scientifically pertinent conferences for disclosing data.
That's great. Thanks a lot. Excited about what's ahead.
Thanks.
Thanks. I really appreciate it, and I appreciate everyone who joined the call. Many thanks for the questions that came in. To wrap up, I'd say we're quite enthusiastic and thrilled about how things have gone so far in Q1 2026. We're truly only at the beginning, and we're hitting the milestones just as we told you we would. Really thrilled about the early data, and really thrilled about the further updates arriving later in the year. With that, I want to say thanks so much, and I believe we'll now end the call.
Appreciate it. That brings today's conference call to a close. We're grateful that all of you joined us. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Evaxion A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Evaxion A/S earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.